当前位置: 首页 > 期刊 > 《中国实用医药》 > 2014年第7期 > 正文
编号:12708413
舍曲林与西酞普兰治疗帕金森病合并抑郁的差别的临床研究(2)
http://www.100md.com 2014年3月5日 牛艳国 李珂 王献 洪丽
第1页

    参见附件。

     [2]Shen CC, Tsai SJ, Perng CL, et al. Risk of Parkinson disease after depression: a nationwide population-based study. Neurology, 2013, 81(17):1538-1544.

    [3]Takahashi K. Non-motor symptoms in premotor phase of Parkinson disease. Rinsho Shinkeigaku, 2013,53(11):974-976.

    [4]Costa FH, Rosso AL, Maultasch H, et al.Depression in Parkinson's disease: diagnosis and treatment. Arq Neuropsiquiatr, 2012, 70(8): 617-620.

    [5]Jefferies AL. Selective serotonin reuptake inhibitors in pregnancy and infant outcomes. Paediatr Child Health, 2011,16(9):562-563.

    [6]Marino S, Sessa E, Di Lorenzo G, et al. Sertraline in the treatment of depressive disorders in patients with Parkinson's disease. Neurol Sci, 2008,29(6):391-395.

    [7]Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord, 2008, 23(6):850-857.

    [8]Rosso AL, Maultasch H, Nicaretta DH, et al. Depression in Parkinson's disease: diagnosis and treatment. Arq Neuropsiquiatr, 2012, 70(8):617-620.

您现在查看是摘要介绍页,详见PDF附件